Funded Biotechnology Startups in Paris
Among the 50 Paris biotechnology rounds shown, Nanobiotix’s $116M (2026-05-21) is the clear outlier: it is the only disclosed amount above $100M, and it si…
Among the 50 Paris biotechnology rounds shown, Nanobiotix’s $116M (2026-05-21) is the clear outlier: it is the only disclosed amount above $100M, and it sits well above the next-largest disclosed rounds such as Cellectis ($80M on 2023-11-01), SparingVision ($75M on 2022-09-14), and Corteria Pharmaceuticals ($70M on 2023-09-07). Disclosed amounts also show a wide floor-to-ceiling span, with the smallest disclosed round at Stimunity’s $900K (2020-05-11).
The timeline concentrates heavily in the most recent window: 2026 accounts for many of the newest entries (e.g., TISSIUM $34M on 2026-06-24, Abivax $45M on 2026-05-05, and Generare $23M on 2026-04-02), while the oldest row dates back to 2020-05-11 (Stimunity). Stage labeling is also skewed toward non-transparent classifications: “Series Unknown” appears 20 times and “undisclosed” appears 5 times, including One Biosciences (undisclosed on 2026-06-18) and PresentID (undisclosed on 2023-12-01).
Most recent rounds
50 shownRelated listings
Frequently asked
What’s the largest disclosed biotech round in Paris on this list, and how extreme is it versus the rest?
Nanobiotix’s $116M on 2026-05-21 is the only disclosed round above $100M in the 50 rows, dwarfing the next-largest disclosed amounts such as Cellectis ($80M on 2023-11-01) and Corteria Pharmaceuticals ($70M on 2023-09-07). On the other end, Stimunity’s $900K on 2020-05-11 is the smallest disclosed amount.
Do the most recent rounds cluster into a narrow date window?
Yes, a large share of the newest activity lands in 2026, with multiple entries in March–June 2026 such as TISSIUM ($34M, 2026-06-24), Nanobiotix ($116M, 2026-05-21), and Abivax ($45M, 2026-05-05). The overall displayed range runs from 2026-06-24 down to 2020-05-11.
How often are rounds labeled opaquely, and which examples show “Series Unknown” or “undisclosed”?
“Series Unknown” appears 20 times, while “undisclosed” appears 5 times with no disclosed amount (for example One Biosciences on 2026-06-18 and Inotrem on 2023-11-06). That means stage or amount transparency is missing for a meaningful portion of the most recent entries.
Is there evidence of a stage mix skew, or recurring named stages among disclosed rounds?
Named stages do recur, including multiple Series A rounds (e.g., Generare $23M on 2026-04-02; Faircraft $16M on 2024-11-21; Coave Therapeutics $33M on 2025-01-09) and multiple Seeds (e.g., Amatera $7M on 2026-03-04; BIOPHTA $7M on 2024-06-03; Home Biosciences $15M on 2021-11-09). However, “Series Unknown” still dominates the labeling in this sample.
Are there standout outliers besides the largest round, worth focusing on for diligence?
Besides the $116M Nanobiotix outlier, the list also contains unusually large disclosed rounds concentrated in specific years: Cellectis at $80M (2023-11-01) and SparingVision at $75M (2022-09-14), both substantially above many mid-single-digit and low-double-digit disclosed rounds. The smallest disclosed amount, Stimunity’s $900K (2020-05-11), is another clear counterpoint.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.